Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
Jerry R. Colca(Rubius Therapeutics (United States)), David G. Orloff(Medpace (United States)), A Shashlo(Metabolic Solutions Development Company (United States)), Rong Zhou(Hunan University), William Graham McDonald(Metabolic Solutions Development Company (United States)), James T. VanderLugt(Metabolic Solutions Development Company (United States)), Jialang Liang(Medpace (United States)), Wade J. Adams(Metabolic Solutions Development Company (United States))
Cited by 83
Related Papers
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
|PLoS ONE|2013|165
Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation
|Journal of Virology|2022|23
Conformations of Human Immunodeficiency Virus Envelope Glycoproteins in Detergents and Styrene-Maleic Acid Lipid Particles
|Journal of Virology|2023|13
Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells
|Gynecologic Oncology|2004|12
Early Wound Repair Versus Later Scar Repair in Children with Treadmill Hand Friction Burns
|Journal of Burn Care & Research|2021|7